Login / Signup

Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol.

Alessandro OttaianoStefania ScalaMariachiara SantorsolaAnna Maria TrottaCrescenzo D'AlterioLuigi PortellaOttavia ClementeAnna NappiNicoletta ZanalettiAlfonso De StefanoAntonio AvalloneVincenza GranataCarmen NotarielloAmalia LuceAngela LombardiCarmine PiconeAntonella PetrilloFrancesco PerriFabiana TatangeloAnnabella Di MauroVittorio AlbinoFrancesco IzzoDaniela RegaUgo PaceMassimiliano Di MarzoPaolo ChiodiniGianfranco De FeoPaola Del PreteGerardo BottiPaolo DelrioMichele CaragliaGuglielmo Nasti
Published in: Therapeutic advances in medical oncology (2021)
The ARBITRATION trial (version 0.0, 13 April 2020) has been registered into the clinicaltrials.gov registry on 20 May 2020 with identifier NCT04397601.
Keyphrases
  • study protocol
  • metastatic colorectal cancer
  • randomized controlled trial
  • clinical trial
  • squamous cell carcinoma
  • small cell lung cancer
  • phase iii
  • open label
  • phase ii
  • combination therapy
  • wild type